Straits Times Index
3,176.51 -11.15 (-0.35%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,224.14 -161.73 (-0.99%) FTSE 100
7,828.83 -48.22 (-0.61%) Bitcoin USD
64,969.86 +2,793.66 (+4.49%) CMC Crypto 200
1,332.86 +20.24 (+1.57%)
Cryo-Cell International, Inc. (CCEL)
After hours:
| Previous close | 6.75 |
| Open | 6.82 |
| Bid | 0.00 x 1800 |
| Ask | 0.00 x 3000 |
| Day's range | 6.79 - 7.80 |
| 52-week range | 3.67 - 8.15 |
| Volume | |
| Avg. volume | 10,485 |
| Market cap | 59.73M |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.16 |
| Earnings date | 12 Jul 2024 - 16 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 01 Sept 2022 |
| 1y target est | 9.00 |
Business WireCord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2024 Financial Results
OLDSMAR, Fla., April 15, 2024--Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the "Company"), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 29, 2024.
Business WireCryo-Cell Announces Plans to Explore Strategic Alternatives and Spin-off Celle Corp. to Maximize Shareholder Value
OLDSMAR, Fla., March 25, 2024--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company" or "Cryo-Cell"), the world’s first private cord blood bank to separate and store stem cells in 1992, today announced that its Board of Directors has authorized the spin-off of its newly formed subsidiary, Celle Corp., to the Cryo-Cell shareholders and to explore all strategic alternatives for Cryo-Cell (post spin-off) to maximize shareholder value, including, but not limited to, equity and/or de
Business WireCryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2023
OLDSMAR, Fla., February 28, 2024--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the "Company"), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2023.
